RE-DUAL PCI亚组分析:房颤患者PCI后达比加群双联治疗在ACS与非ACS及替格瑞洛或氯吡格雷亚组中的一致性
RE-DUAL PCI预设亚组分析纳入2725例房颤PCI患者,比较达比加群110mg或150mg联合P2Y12抑制剂与华法林三联治疗。在ACS或择期PCI、替格瑞洛或氯吡格雷亚组中,达比加群双联治疗降低出血风险的效果一致,交互P均>0.10;死亡、心梗、卒中、体循环栓塞或非计划血运重建复合终点与华法林三联相当。
要点
- 房颤PCI后达比加群双联较华法林三联降低出血风险,各亚组一致。
- ACS与择期PCI亚组、替格瑞洛与氯吡格雷亚组交互P均>0.10。
- 达比加群双联与华法林三联在死亡、心梗、卒中、栓塞或非计划血运重建复合终点相当。
核心结论
- 达比加群110mg和150mg双联治疗较华法林三联降低出血风险,在ACS与非ACS及替格瑞洛或氯吡格雷亚组中获益一致。
- 达比加群双联与华法林三联在死亡、心肌梗死、卒中、体循环栓塞或非计划血运重建复合终点上相当,亚组间交互P均>0.10。
研究设计与样本
- RE-DUAL PCI试验的预设亚组分析,纳入2725例房颤PCI患者随机接受达比加群110mg或150mg联合P2Y12抑制剂,或华法林联合P2Y12抑制剂和阿司匹林。
- 平均随访14个月,50.5%患者因ACS行PCI,12%患者接受替格瑞洛治疗。
主要发现
- ACS患者主要终点(大出血或临床相关非大出血)风险:达比加群110mg HR 0.47(95%CI 0.35-0.63),150mg HR 0.67(95%CI 0.50-0.90)。
- 择期PCI患者主要终点风险:达比加群110mg HR 0.57(95%CI 0.43-0.76),150mg HR 0.76(95%CI 0.56-1.03)。
- 接受替格瑞洛患者主要终点风险:达比加群110mg HR 0.46(95%CI 0.28-0.76),150mg HR 0.59(95%CI 0.34-1.04)。
- 接受氯吡格雷患者主要终点风险:达比加群110mg HR 0.51(95%CI 0.41-0.64),150mg HR 0.73(95%CI 0.58-0.91)。
- 所有亚组交互P值均>0.10;复合终点在各亚组间有轻微差异,交互P值均>0.10。
关键数值与推荐
- 主要终点为大出血或临床相关非大出血事件。
- 达比加群双联方案包括达比加群110mg或150mg联合P2Y12抑制剂(替格瑞洛或氯吡格雷)。
- 对照方案为华法林联合P2Y12抑制剂和阿司匹林的三联治疗。
临床怎么用
- 房颤患者PCI后,无论因ACS还是择期PCI,无论合用替格瑞洛还是氯吡格雷,达比加群双联治疗较华法林三联均可降低出血风险。
- 达比加群双联治疗在死亡、心梗、卒中、体循环栓塞或非计划血运重建复合终点上与华法林三联相当,可作为房颤PCI后抗栓治疗选择。
局限性
- 本文为RE-DUAL PCI试验的亚组分析,亚组样本量较小可能影响统计效能。
- 接受替格瑞洛治疗的患者仅占12%,该亚组结果需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: After percutaneous coronary intervention (PCI) in patients with atrial fibrillation, safety and efficacy with dabigatran dual therapy were evaluated in pre-specified subgroups of patients undergoing PCI due to acute coronary syndrome (ACS) or elective PCI, and those receiving ticagrelor or clopidogrel treatment. METHODS AND RESULTS: In the RE-DUAL PCI trial, 2725 patients were randomized to dabigatran 110 mg or 150 mg with P2Y12 inhibitor, or warfarin with P2Y12 inhibitor and aspirin. Mean follow-up was 14 months, 50.5% had ACS, and 12% received ticagrelor. The risk of the primary endpoint, major or clinically relevant non-major bleeding event, was reduced with both dabigatran dual therapies vs. warfarin triple therapy in patients with ACS [hazard ratio (95% confidence interval), 0.47 (0.35-0.63) for 110 mg and 0.67 (0.50-0.90) for 150 mg]; elective PCI [0.57 (0.43-0.76) for 110 mg and 0.76 (0.56-1.03) for 150 mg]; receiving ticagrelor [0.46 (0.28-0.76) for 110 mg and 0.59 (0.34-1.04) for 150 mg]; or clopidogrel [0.51 (0.41-0.64) for 110 mg and 0.73 (0.58-0.91) for 150 mg], all interaction P-values >0.10. Overall, dabigatran dual therapy was comparable to warfarin triple therapy for the composite endpoint of death, myocardial infarction, stroke, systemic embolism, or unplanned revascularization, with minor variations across the subgroups, all interaction P-values >0.10. CONCLUSION: The benefits of both dabigatran 110 mg and 150 mg dual therapy compared with warfarin triple therapy in reducing bleeding risks were consistent across subgroups of patients with or without ACS, and patients treated with ticagrelor or clopidogrel.
引用
- Oldgren J, Steg PG, Hohnloser SH, et al. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J. 2019. PMID: 30793734. doi:10.1093/eurheartj/ehz059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。